<?xml version="1.0" encoding="UTF-8"?>
<document id="DrugDDI.d536" origId="Dapsone"><sentence id="DrugDDI.d536.s0" origId="s0" text="A drug-drug interaction study evaluated the effect of the use of ACZONE Gel, 5%, in combination with double strength (160 mg/800 mg) trimethoprim/sulfamethoxazole (TMP/SMX)."><entity id="DrugDDI.d536.s0.e0" origId="s0.p12" charOffset="133-145" type="drug" text="trimethoprim"/><entity id="DrugDDI.d536.s0.e1" origId="s0.p13" charOffset="146-162" type="drug" text="sulfamethoxazole"/><entity id="DrugDDI.d536.s0.e2" origId="s0.p15" charOffset="164-167" type="drug" text="TMP"/><pair id="DrugDDI.d536.s0.p0" e1="DrugDDI.d536.s0.e0" e2="DrugDDI.d536.s0.e1" interaction="false"/><pair id="DrugDDI.d536.s0.p1" e1="DrugDDI.d536.s0.e0" e2="DrugDDI.d536.s0.e2" interaction="false"/><pair id="DrugDDI.d536.s0.p2" e1="DrugDDI.d536.s0.e1" e2="DrugDDI.d536.s0.e2" interaction="false"/></sentence><sentence id="DrugDDI.d536.s1" origId="s1" text="During co-administration, systemic levels of TMP and SMX were essentially unchanged."><entity id="DrugDDI.d536.s1.e0" origId="s1.p20" charOffset="45-48" type="drug" text="TMP"/></sentence><sentence id="DrugDDI.d536.s2" origId="s2" text="However, levels of dapsone and its metabolites increased in the presence of TMP/SMX."><entity id="DrugDDI.d536.s2.e0" origId="s2.p28" charOffset="19-26" type="drug" text="dapsone"/><entity id="DrugDDI.d536.s2.e1" origId="s2.p30" charOffset="35-46" type="drug" text="metabolites"/><entity id="DrugDDI.d536.s2.e2" origId="s2.p33" charOffset="76-79" type="drug" text="TMP"/><pair id="DrugDDI.d536.s2.p0" e1="DrugDDI.d536.s2.e0" e2="DrugDDI.d536.s2.e1" interaction="false"/><pair id="DrugDDI.d536.s2.p1" e1="DrugDDI.d536.s2.e0" e2="DrugDDI.d536.s2.e2" interaction="true"/><pair id="DrugDDI.d536.s2.p2" e1="DrugDDI.d536.s2.e1" e2="DrugDDI.d536.s2.e2" interaction="true"/></sentence><sentence id="DrugDDI.d536.s3" origId="s3" text="Systemic exposure (AUC0-12) of dapsone and N-acetyl-dapsone (NAD) were increased by about 40% and 20% respectively in presence of TMP/SMX."><entity id="DrugDDI.d536.s3.e0" origId="s3.p39" charOffset="31-38" type="drug" text="dapsone"/><entity id="DrugDDI.d536.s3.e1" origId="s3.p41" charOffset="52-59" type="drug" text="dapsone"/><entity id="DrugDDI.d536.s3.e2" origId="s3.p43" charOffset="61-64" type="drug" text="NAD"/><entity id="DrugDDI.d536.s3.e3" origId="s3.p52" charOffset="130-133" type="drug" text="TMP"/><pair id="DrugDDI.d536.s3.p0" e1="DrugDDI.d536.s3.e0" e2="DrugDDI.d536.s3.e1" interaction="false"/><pair id="DrugDDI.d536.s3.p1" e1="DrugDDI.d536.s3.e0" e2="DrugDDI.d536.s3.e2" interaction="false"/><pair id="DrugDDI.d536.s3.p2" e1="DrugDDI.d536.s3.e0" e2="DrugDDI.d536.s3.e3" interaction="true"/><pair id="DrugDDI.d536.s3.p3" e1="DrugDDI.d536.s3.e1" e2="DrugDDI.d536.s3.e2" interaction="false"/><pair id="DrugDDI.d536.s3.p4" e1="DrugDDI.d536.s3.e1" e2="DrugDDI.d536.s3.e3" interaction="true"/><pair id="DrugDDI.d536.s3.p5" e1="DrugDDI.d536.s3.e2" e2="DrugDDI.d536.s3.e3" interaction="false"/></sentence><sentence id="DrugDDI.d536.s4" origId="s4" text="Notably, systemic exposure (AUC0-12) of dapsone hydroxylamine (DHA) was more than doubled in the presence of TMP/SMX."><entity id="DrugDDI.d536.s4.e0" origId="s4.p59" charOffset="40-61" type="drug" text="dapsone hydroxylamine"/><entity id="DrugDDI.d536.s4.e1" origId="s4.p68" charOffset="109-112" type="drug" text="TMP"/><pair id="DrugDDI.d536.s4.p0" e1="DrugDDI.d536.s4.e0" e2="DrugDDI.d536.s4.e1" interaction="true"/></sentence><sentence id="DrugDDI.d536.s5" origId="s5" text="Exposure from the proposed topical dose is about 1% of that from the 100 mg oral dose, even when co-administered with TMP/SMX."><entity id="DrugDDI.d536.s5.e0" origId="s5.p79" charOffset="118-121" type="drug" text="TMP"/></sentence><sentence id="DrugDDI.d536.s6" origId="s6" text="Certain concomitant medications (such as rifampin, anticonvulsants, St."><entity id="DrugDDI.d536.s6.e0" origId="s6.p81" charOffset="20-31" type="drug" text="medications"/><entity id="DrugDDI.d536.s6.e1" origId="s6.p83" charOffset="41-49" type="drug" text="rifampin"/><entity id="DrugDDI.d536.s6.e2" origId="s6.p84" charOffset="51-66" type="drug" text="anticonvulsants"/><pair id="DrugDDI.d536.s6.p0" e1="DrugDDI.d536.s6.e0" e2="DrugDDI.d536.s6.e1" interaction="false"/><pair id="DrugDDI.d536.s6.p1" e1="DrugDDI.d536.s6.e0" e2="DrugDDI.d536.s6.e2" interaction="false"/><pair id="DrugDDI.d536.s6.p2" e1="DrugDDI.d536.s6.e1" e2="DrugDDI.d536.s6.e2" interaction="false"/></sentence><sentence id="DrugDDI.d536.s7" origId="s7" text="John?s wort) may increase the formation of dapsone hydroxylamine, a metabolite of dapsone associated with hemolysis."><entity id="DrugDDI.d536.s7.e0" origId="s7.p91" charOffset="68-78" type="drug" text="metabolite"/><entity id="DrugDDI.d536.s7.e1" origId="s7.p92" charOffset="82-89" type="drug" text="dapsone"/><pair id="DrugDDI.d536.s7.p0" e1="DrugDDI.d536.s7.e0" e2="DrugDDI.d536.s7.e1" interaction="false"/></sentence><sentence id="DrugDDI.d536.s8" origId="s8" text="With oral dapsone treatment, folic acid antagonists such as pyrimethamine have been noted to possibly increase the likelihood of hematologic reactions"><entity id="DrugDDI.d536.s8.e0" origId="s8.p95" charOffset="10-17" type="drug" text="dapsone"/><entity id="DrugDDI.d536.s8.e1" origId="s8.p96" charOffset="29-51" type="drug" text="folic acid antagonists"/><entity id="DrugDDI.d536.s8.e2" origId="s8.p97" charOffset="60-73" type="drug" text="pyrimethamine"/><pair id="DrugDDI.d536.s8.p0" e1="DrugDDI.d536.s8.e0" e2="DrugDDI.d536.s8.e1" interaction="true"/><pair id="DrugDDI.d536.s8.p1" e1="DrugDDI.d536.s8.e0" e2="DrugDDI.d536.s8.e2" interaction="true"/><pair id="DrugDDI.d536.s8.p2" e1="DrugDDI.d536.s8.e1" e2="DrugDDI.d536.s8.e2" interaction="false"/></sentence><sentence id="DrugDDI.d536.s9" origId="s9" text="."/><sentence id="DrugDDI.d536.s10" origId="s10" text="?"/></document>